Akouos Raises Over $200M in IPO

Boston-based biotech Akouos has raised gross proceeds of $244 million in its June stock market debut. Akouos is a precision genetic medicine company dedicated to developing gene therapies for people worldwide who live with disabling hearing loss. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy. (Source: Akouos Website, 30 June, 2020)